Abstract: Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel.

Abstract: The present invention provides the use of pelorol analogs of Formula, (I) and pharmaceutical compositions thereof as modulators of SHIP 1 activity. A compound or a pharmaceutical composition of the present invention may be used for the treatment or prophylaxis of an inflammatory, neoplastic, hematopoetic or immune disorder or condition in addition to other disorders and conditions.

Abstract: A novel class of compounds to inactivate autotaxin enzymes is provided. Such compounds include mono- and di-fluoromethylphenyl C12-C18 phosphodiesters and exhibit reactivity with autotaxin to ultimately reduce the size of the reactive sites thereon to prevent conversion of lysophosphatidyl choline to lysophophatidic acid. Furthermore, such compounds are non-cytotoxic, and can be incorporated within delivery forms for human ingestion. As such, these compounds accord an excellent manner of potentially reducing generation of certain cancers attributable to the presence of naturally occurring autotaxin within the human body. Methods of producing such novel compounds are encompassed within this invention as well as methods of inactivating autotaxin to certain degrees therewith.

Abstract: A PEPCK inhibitor can include identifying a molecule that has a size capable of fitting into and interacting with the PEPCK binding site and at least one of the following: (a) a first terminal substituent having co-planar atoms acting as metal ligands to the active site metal ion PEPCK; (b) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent includes a neutral carbon center or include an oxygen, sulfur, selenium, or other atom with similar physiochemical properties; (c) at least one of an atom or substituent at positions 2 or 3 from the first terminal substituent is devoid of an electropositive atom or substituents; or (d) a second terminal substituent opposite of the first terminal substituent, said second terminal substituent having an atom that is a hydrogen boding acceptor and/or is negatively charged.

Abstract: Described herein are novel compounds having antineoplastic and antimicrobial activity, obtained via structural modifications of resveratrol and combretastatin A-4, methods for synthesis of these compounds, and their use in pharmaceutical composition and for use in the treatment of mammals having cancer. Examples of the novel compounds are: (Z)- and (E)-3,4?,5-trimethoxystilbene (4a, 4b); (Z)- and (E)-3,5-dimethoxy-4?-hydroxystilbene (14c, 14d); (Z)- and (E)-3-hydroxy-4?,5-dimethoxystilbene (14g, 14h); (Z)- and (E)-3,5-dihydroxy-4?-methoxy-stilbene (14k, 14l); sodium resverastatin dibenzyl phosphate ((Z)-3,5-dimethoxy-4-[O-bis(benzyl)phosphoryl]-stilbene) (14m); and sodium resverastatin phosphate (14n).

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

Abstract: Benzoylresorcinol-based phosphate esters are obtained by reacting a benzoylresorcinol compound with a chlorophosphate. The benzoylresorcinol-based phosphate esters can function as flame retardants and/or UV stabilizers for polycarbonates (PC), poly(phenylene oxide) (PPO), polyesters (e.g., PET and PBT), polycarbonate and acrylonitrile-butadiene-styrene terpolymer (PC/ABS) blends, poly(phenylene oxide) and high-impact polystyrene (PPO/HIPS) blends and other polymers. The benzoylresorcinol-based phosphate ester flame retardants may possess enhanced thermal stability compared to resorcinol based phosphate ester (RDP). Synthetic procedures and applications of the benzoylresorcinol-based phosphate esters compounds are provided.

Abstract: Flavan-based and spirodichroman compound-based phosphate esters prepared by reacting flavans and spirodichroman compounds with phosphorus oxychloride, monophenyl dichlorophosphate, or diphenyl chlorophosphate compounds are described. The flavans and spirodichroman compounds can be synthesized by the reaction of resorcinol with aliphatic acetone. Such phosphate esters can be used as flame retardants.

Abstract: The invention relates to novel compounds denominated halocombstatins. The halocombstatins are derivatives of combretastatin A-3, and include compounds that exhibit cancer growth cell inhibition against a panel of human cancer cell lines and the murine P388 leukemia, as well as activity as inhibitors of tubulin polymerization and inhibitors of the binding of colchicine to tubulin.

Abstract: Compositions for the inhibition of the formation of new vaculature by angiogenesis are provided as in compounds which are salts comprising as an acidic component a compound of formula (1) wherein: R1, R2 and R3 are each independently alkyl, R4 is alkoxy, haloalkoxy, alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl, hydroxy or halo, R5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy, phosphate or halo, and, as the basic component, a compound selected from the group consisting of (2) a compound of formula (2) wherein R6 is hydrogen or alkyl R7 is alkyl, alkylamino, dialkylamino, nitroamino, hydrazine, mercapto or alkylthio X is CH2, CH2CH2, CH2S, CH2CH2S Y is NH or S or a compound of formula (3) wherein R8 is alkyl or aminoalkyl R9 is hydrogen, alkyl or optionally substituted phenyl or, a compound of formula (4) wherein Z is O, S, CH2, CHR13 or a bond R10, R11, R12 and R13 are each independently alkyl or hydrogen or, a compound of formula (5) wherein R14 is alkyl and the pharmaceutic

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: Methods of synthesizing a phosphate ester of combretastatin A-4 and trans-isomers thereof in which combretastatin A-4 is reacted with dibenzylphosphite in the presence of carbon tetrabromide, or with 2,2,2-trichloroethyl phosphorodichloridate, to form a phosphate ester of combretastatin A-4 with protecting groups thereon.

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: The subject invention provides compounds useful as fluorogenic substrates for the hydrolytic enzymes. Upon hydrolysis of the hydrolyzable group, a halo-pyrene substituted molecule is developed which is highly fluorescent, water soluble and exhibits several desirable characteristics, including a large Stokes' shift.

Abstract: The isomerization of an alkylated phenol composition that contains an ortho-alkyl substituted phenol component to isomerize and reduce the level of ortho-alkyl substituted phenol component therein can be accomplished by heating that composition in the presence of a catalytically effective amount of a solid acid catalyst to carry out such isomerization and reduction in the level of ortho-alkyl substituted phenol. Examples of suitable solid acid catalysts can be selected from the H-form zeolites, the supported sulfonic acids, and the heteropoly acids. The resulting isomerized product can be subsequently phosphorylated.

Abstract: Provided herein are novel and useful combretastatin A-4 prodrug salts that increase the solubility of combretastatin A-4, readily regenerate combretastatin A-4 in vivo under normal physiological conditions, and which produce physiologically tolerable products as a result of the regeneration of combretastatin A-4.

Abstract: The present invention discloses phosphoric triesters represented by formula (1): wherein R1 represents C12-C24 alkyl or alkenyl, R2 represents C6-C24 alkyl, alkenyl, or aryl, and R3 represents C1-C6 alkyl, C2-C6 alkenyl, or aryl; external compositions containing the phosphoric triesters; and methods for preparing asymmetric phosphoric triesters. The compositions of the present invention have excellent compatibility with the skin, good sensation during use, and a high degree of safety.

Abstract: A chemiluminescent 1,2-dioxetane derivative having a formula (I): ##STR1## wherein R.sup.1 and R.sup.4 each represent, individually, hydrogen, an alkyl group, an alkoxyl group, a hydroxyl group, or --OS;(R.sup.9 R.sup.10 R.sup.11) in which R.sup.9, R.sup.10 and R.sup.11 each represent an alkyl group; R.sup.2, R.sup.3, R.sup.5 and R.sup.6 each represent, individually, hydrogen or an alkyl group, provided that R.sup.2, R.sup.3, R.sup.5 and R.sup.6 each cannot be hydrogen at the same time, and that R.sup.2 and R.sup.3, and R.sup.5 and R.sup.6, each taken together, can form a cycloalkyl group; R.sup.7 represents an alkyl group; R.sup.8 represents hydrogen, an alkoxyl group, a phosphate salt group, or --OSi(R.sup.9 R.sup.10 R.sup.11); intermediates for synthesizing the above 1,2-dioxetane derivative; and methods of producing the intermediates are provided.

Abstract: Described are preferred suicide inhibitors of phosphatase or phosphodiesterase enzymes, and methods for preparing halo enol phosphates which can serve as such suicide inhibitors.

Abstract: Disclosed herein are Combretastatin A-4 Prodrugs, having the general strure set forth below, which are useful in the treatment of one or more neoplastic diseases by means of chemotherapy.

Abstract: Alkyl glycidol ether/dithiophosphoric acid addition products corresponding to the following general formula:[R.sup.1 ]O[C(H)(H)][C(H)C(H)(H)(OH)(R.sup.4)] (I)in whichR.sup.4 =[(R.sup.2 O)(R.sup.3 O)]P(S)S,R.sup.1 . . . R.sup.3 =alkyl, aryl,a process for the production of the adducts from the corresponding dithiophosphoric acids and glycidol ethers and the use of the addition products as lubricant additives in lubricants based on mineral oils or native oils.

Abstract: Disclosed is a process for preparing carbonic diester comprising the formation of carbonic diester by the vapor phase catalytic reaction of an alkyl nitrite and carbon monoxide in the presence of a solid catalyst, wherein platinum group metal ion in the solid catalyst is exchanged on an ion exchange zeolite carrier.

Abstract: A compound represented by the following general formula I; ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 independently represent a hygrogen atom, alkyl group or aryl group, provided that at least one of R.sup.1, R.sup.2 and R.sup.3 represents 3,7,11,15-tetramethylhexadecyl group, 3,7,11-trimethyldodecyl group or 3,7-dimethyloctyl group, or a salt thereof. The compound may have R- or S- configuration with respect to each asymmetric carbon contained therein and it may be present as a racemate. The compounds of the present invention are useful as surfactants, lubricants, dispersants, emulsifiers, additives, stabilizers, solubilizers, water-repellants, antistatic agents and the like.

Abstract: Amine salts of phosphorothioic acids, useful for example in lubricant compositions, are made by forming a mixture of sulphur and an amine, and then adding a phosphite ester. The reaction is controlled by the rate of addition of the ester.

Abstract: Oil-in-water emulsions (microemulsions) containing 0.01-80% by weight of at least one agrochemical active substance of low water-solubility, one active substance for combating pests in the domestic and hygiene sector and/or one pharmacologically active substance, 1% to 30% by weight of an emulsifier mixture of non, ionic and anionic compounds and at least one alkylarylsulfonic acid salt, as defined in the description, as well as water and, if appropriate, 1% to 30% by weight of at least one solvent of low water-miscibility and/or one solubilizer, and if appropriate 0.05% to 15% by weight of additives, the sum of the components in each case being 100% by weight, a process for the preparation of these aqueous microemulsions and their use.

Abstract: A process for the preparation of 4-O-phosphates of dopamine and dopamine derivatives by treatment of a mixture of both 3-O-phosphate and 4-O-phosphate isomers with a strong mineral acid and optional esterification of the so obtained phosphoric ester of dopamine or dopamine derivatives is described.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphonothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal --0-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate, phosphorochloridothioate, phosphonochloridate or phosphonochloridothioate under alkaline conditions in the presence of a tertiary amine catalyst and a nonionic surfactant having an HLB Value of from about 1 to about 20, preferably about 5 to 15, in a two-phase system, one phase being primarily the phosphorate or phosphonate reactant and a complex thereof with the tertiary amine catalyst and the other phase being an aqueous reaction medium comprising water, a buffer system, and the alkali metal or alkaline earth metal-O-phenyl or --O-N-heterocyclic compound, in the substantial or complete absence of an organic solvent the aqueous reaction medium being maintained at pH about 10 to 12 by the buffer system.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal -O-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate or phosphorochloridothioate under alkaline conditions in a liquid reaction medium and in the presence of a tertiary amine catalyst and a nonionic surfactant having a HLB Value of from about 2.5 to about 20 or more.

Abstract: Hydrolyzable substrates for acid and alkaline phosphatases comprise blocked dye moieties which, when cleaved from the substrate during hydrolysis, provide fluorescent dyes having maximum absorptions above about 530 nm and maximum fluorescent emissions at least about 580 nm. The dyes are blocked prior to hydrolysis with a phosphono or thioxophosphono group or a salt thereof. These substrates can be used in analytical determinations of acid or alkaline phosphatase, or in competitive binding reactions to determine immunologically reactive substances.

Abstract: Disclosed are novel phosphoric ester derivatives of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each represents a lower alkyl group; R.sup.3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a lower alkylthio group; X.sup.1 and X.sup.2 are the same or different and each represents a hydrogen atom or a halogen atom; and Y represents an oxygen atom or a sulfur atom, and insecticidal and miticidal compositions containing said derivatives.